Masters of Health Magazine November 2022 | Page 11

Dr McCullough testified in the US Senate on January 24, 2022, that going forward 95% of all COVID-19 hospitalizations and deaths are avoidable with multidrug treatment.[vii] 

He emphasized in Texas Senate Testimony on June 27, 2022, that physicians have always had a duty to treat or refer ambulatory high-risk patients with COVID-19 so they could benefit from the “community standard of care.”[viii]  Take a look at people in your circle who required hospitalization or even worse, died in the hospital—did they get the full McCullough Protocol© or an alternate regimen (FLCCC, ALFDS, Zelenko, Raoult, Barrientos, Chetty) during the days and weeks before admission?  Were prehospital drugs continued via medication reconciliation once hospitalized?  From the very first patient with the novel coronavirus to those falling ill at this time, outpatient physicians and mid-level providers are bolstered by Article 37 of the 2013 Declaration of Helsinki which essentially says that “unproven” interventions may be used after informed consent when in the doctor’s judgment it “offers hope of saving life, re-establishing health or alleviating suffering.”  Conclusive randomized, blinded, placebo-controlled trials of outpatient multidrug regimens are not forthcoming.  Such trials would require sample sizes of 20,000 to 40,000 patients.  Rather, ambulatory treatment of COVID-19 has evolved relying on clinical judgement and the use of drugs with a signal of benefit and acceptable safety in line with the 21st Century Cures Act.[ix] 

One of the greatest crimes of all-time has been the systematic suppression and oblivion to early therapy over course of the crisis.  We explore how therapeutic nihilism swept across the globe to cause catastrophic harm in our book “Courage to Face COVID-19:  Preventing Hospitalizations and Deaths while Battling the Biopharmaceutical Complex.”[x]

Read Footnotes on page 12